Issued 2026-08-13 at $25.27 · now $24.82 (2026-08-13, −1.8% since)
Based on its own history, a month from the 2026-08-13 close, DNLI has typically landed between $19.72 and $32.09 — a range of −22.0% to +27.0% from the issuance price $25.27.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,159 overlapping 1 month windows · 2017-12-08 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($25.27) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where DNLI has typically landed a month from the 2026-08-13 close of $25.27 — the range is history, not a prediction.
- now $24.82 (-1.8%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $25.03 (-1.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $22.53–$27.52
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $19.72–$32.09
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-13 | −44.4% | −44.4% | +2.7% |
| 2020-02-11 | −39.0% | −39.0% | +6.6% |
| 2020-02-18 | −37.3% | −45.8% | +0.0% |
| 3 best | |||
| 2022-06-16 | +69.6% | +0.0% | +69.6% |
| 2022-06-14 | +61.9% | −0.2% | +61.9% |
| 2020-10-14 | +60.7% | −8.8% | +60.7% |
2,159 overlapping windows · 2017-12-08 – 2026-08-13 · not cherry-picked
Pending catalysts
- December 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) (source, as of 2026-08-14)
- March 2027 — Trial primary completion: Phase 2 primary completion: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 (source, as of 2026-08-14)
- December 2027 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (source, as of 2026-08-14)
- August 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) (source, as of 2026-08-14)
- February 2031 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.